Latest Content

FDA has expanded Capvaxive's indication to high-risk children and adolescents aged 2 through 17 who have completed a primary pneumococcal series, making it the only conjugate vaccine in the U.S. specifically studied and approved for this population.

FDA has approved Utebzi as the first oral carbapenem antibiotic for complicated urinary tract infections, giving patients and providers an alternative to intravenous-only carbapenem therapy.

Biogen has agreed to acquire private immunology biotech RayThera for up to $1 billion, adding a suite of undisclosed small molecule anti-inflammatory candidates to its pipeline.

Brian Hilberdink, president of U.S. Human Pharma, Boehringer Ingelheim, explains what sets his company's obesity strategy apart in an increasingly crowded field.

Marketers must navigate a new landscape that sees customers expecting highly-personalized experiences that mirror their experiences with non-health brands.

Novavax’s EVP of corporate affairs and head of its Sweden division discusses new vaccine technologies, such as its adjuvant matrix technology, are bringing new players into the space.

In today's Pharmaceutical Executive Daily, FDA staff release briefing documents flagging evidence gaps in Moderna's mRNA flu vaccine, a pharma roundup covers Merck's $510 million collaboration with Protillion Biosciences and Jazz Pharmaceuticals' multi-program antibody discovery deal with AbCellera, and Jack McFeely argues that behavioral and engagement insights are the missing ingredient in patient support programs that struggle to sustain long-term persistence.

As Connecticut moves to rein in private equity's playbook in hospital deals, pharma and life sciences leaders face a parallel question: can "Healthcare Stewardship Capital" reconcile investor returns with patient welfare?

FDA scientists have flagged evidence gaps in Moderna's mRNA flu vaccine mFlusiva ahead of an advisory committee vote, raising questions about its performance across influenza strains, high-risk patient subgroups, and co-administration scenarios.

Brian Hilberdink, president of U.S. Human Pharma, Boehringer Ingelheim, notes how the real obstacle in obesity care isn't how a drug is delivered, it's whether patients stay on treatment long enough to achieve lasting metabolic health.

Behavioral and engagement insights are helping biopharma companies design more personalized patient support programs that improve persistence and long-term outcomes.

Silvia Taylor of Novavax explains how major biotechs like Eli Lilly and Sanofi are developing vaccine strategies for the coming years.

5 Prime Sciences CEO discusses how simply building a massive data set can cause more problems than it solves during clinical trials.